| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | hK2, hGK-1, KLK2A2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human KLK2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于KLK2抗体的3篇参考文献摘要示例(注：文献信息为模拟示例，非真实存在)：
---
1. **文献名称**: *Development of a Monoclonal Antibody Specific for Human Glandular Kallikrein 2 (hK2) and Its Application in Prostate Cancer Diagnostics*
**作者**: Young CY, et al.
**摘要**: 本研究开发了一种高特异性的抗人KLK2单克隆抗体，通过免疫印迹和免疫组化验证其在前列腺组织中的选择性识别能力。该抗体可用于区分前列腺癌与良性增生，并证实KLK2在前列腺癌组织中的过表达与肿瘤进展相关。
---
2. **文献名称**: *Characterization of KLK2-Specific Antibodies for Targeted Therapy in Androgen-Independent Prostate Cancer*
**作者**: Darson MF, et al.
**摘要**: 研究团队通过噬菌体展示技术筛选出靶向KLK2的人源化抗体，并在体外和小鼠模型中验证其抑制肿瘤细胞侵袭的作用。抗体通过阻断KLK2与细胞外基质的相互作用，显著降低转移潜能，提示其作为治疗性抗体的潜力。
---
3. **文献名称**: *KLK2 as a Serum Biomarker: Validation of a Novel ELISA Assay Using Dual-Antibody Sandwich Technology*
**作者**: Lövgren J, et al.
**摘要**: 该研究建立了一种基于双抗夹心法的KLK2血清检测方法，使用两种高亲和力单克隆抗体分别作为捕获和检测抗体。临床样本分析表明，该方法灵敏度显著优于传统PSA检测，尤其在低浓度范围内具有诊断优势。
---
**注**：以上文献为示例性质，实际文献需通过PubMed或Web of Science等平台检索关键词(如"KLK2 antibody"或"hK2 prostate cancer")获取。真实研究多聚焦于KLK2在前列腺癌诊断/治疗中的抗体开发与应用。
KLK2 (kallikrein-related peptidase 2) is a serine protease encoded by the *KLK2* gene, part of the tissue kallikrein family located on chromosome 19q13.4. Primarily expressed in the prostate gland, KLK2 is regulated by androgens and shares structural and functional similarities with KLK3 (prostate-specific antigen, PSA). It plays a role in seminal fluid liquefaction and extracellular matrix remodeling by cleaving substrates like semenogelin and insulin-like growth factor-binding proteins. Elevated KLK2 levels are associated with prostate cancer (PCa), where it serves as a complementary biomarker to PSA for diagnosis, prognosis, and monitoring disease progression.
KLK2 antibodies are immunological tools developed to detect and quantify KLK2 protein expression in research and clinical settings. These antibodies, often monoclonal or polyclonal, enable techniques like immunohistochemistry, ELISA, and Western blotting to study KLK2's tissue distribution, secretion patterns, and relationship to tumor aggressiveness. In PCa, KLK2 antibodies aid in differentiating malignant from benign conditions and assessing metastatic potential. Recent research explores their therapeutic potential, including antibody-drug conjugates or immune-targeting strategies. However, challenges remain in optimizing specificity and minimizing cross-reactivity with homologous kallikreins. Ongoing studies aim to refine KLK2 antibody applications for precision oncology and non-invasive liquid biopsies.
×
